Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM -0.85%86 EV-to-EBIT is 22.59 as of Aug. 03, 2026, which is 44% below its 10-year median of 40.13. GuruFocus rates LTS:0JDM with a GF Score™ of 86/100 and a GF Value™ of $245.45 (Fairly Valued). The stock has 8 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 50.48% on this metric.
The historical rank and industry rank for IQVIA Holdings's EV-to-EBIT or its related term are showing as below:
LTS:0JDM'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.89 Med: 40.13 Max: 66.77
Current: 22.59
During the past 13 years, the highest EV-to-EBIT of IQVIA Holdings was 66.77. The lowest was 14.89. And the median was 40.13.
LTS:0JDM's EV-to-EBIT is ranked better than 50.48% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.07
vs LTS:0JDM: 22.59
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
IQVIA Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $45,899 Mil.
IQVIA Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,345 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings EV-to-EBIT Related Terms
IQVIA Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IQVIA Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's EV-to-EBIT falls into.
IQVIA Holdings's current Enterprise Value is $52,975 Mil.
IQVIA Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,345 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (LTS:0JDM) has a EV-to-EBIT of 22.59 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on IQVIA Holdings and its competitors. This is 44% below median its historical median of 40.13. Over the past decade, IQVIA Holdings' EV-to-EBIT has ranged from 14.89 to 66.77. According to the industry distribution chart, IQVIA Holdings ranks #52 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 49.5%.
Is IQVIA Holdings' EV-to-EBIT too high?
IQVIA Holdings' current EV-to-EBIT of 22.59 is 44% below median its 10-year median of 40.13. Over the past 10 years, this metric has ranged from a low of 14.89 to a high of 66.77. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.07. IQVIA Holdings' value of 22.59 is 2.1% below this industry median. Based on the distribution chart, IQVIA Holdings ranks #52 out of 105 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' EV-to-EBIT compare to WAT and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #52 out of 105 companies for EV-to-EBIT. This puts IQVIA Holdings in the upper half of its industry. The industry median EV-to-EBIT is 23.07. IQVIA Holdings' value of 22.59 is 2.1% below this benchmark. Historically, IQVIA Holdings' own EV-to-EBIT has ranged from 14.89 to 66.77 over the past decade. While the company's 10-year median is 40.13 vs. the industry median of 23.07, IQVIA Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.07, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current EV-to-EBIT of 22.59 is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current EV-to-EBIT is 22.59, which is 44% below median its own 10-year median of 40.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Fairly Valued. The stock's GF Value™ is $245.45, compared to a current price of $234.50 — trading 4.5% below its estimated fair value. The current EV-to-EBIT is 22.59, which is 44% below median its 10-year median of 40.13 and 2.1% below the Medical Diagnostics & Research industry median of 23.07. IQVIA Holdings' overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current EV-to-EBIT is 22.59 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $234.50 is trading 4.5% below its estimated GF Value™ of $245.45.
GuruFocus considers IQVIA Holdings to be Fairly Valued.
Key valuation signals for LTS:0JDM:
EV-to-EBIT: 22.59 (44% below median its 10-year median of 40.13)
GF Value™: $245.45 vs. price of $234.50 (4.5% below fair value)
Industry Position: 2.1% below the Medical Diagnostics & Research median (#52 of 105)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
86GF Score
Get the complete analysis for LTS:0JDM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
